A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.

Mark Agulnik,Nizar M. Tannir,Joseph Gerald Pressey,Mrinal M. Gounder,Gregory M. Cote,Maria Roche,Susan Doleman,Stephen J. Blakemore,Alicia Clawson,Scott R. Daigle,Jeanie Tang,Peter Ho,George D. Demetri

A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.

2016

Mark Agulnik
Nizar M. Tannir
Joseph Gerald Pressey
Mrinal M. Gounder
Gregory M. Cote
Maria Roche
Susan Doleman
Stephen J. Blakemore
Alicia Clawson
Scott R. Daigle
Jeanie Tang
Peter Ho
George D. Demetri

TPS11071Background: Tazemetostat is a potent and selective inhibitor of the histone methyltransferase enhancer of zeste-homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 ...

Keywords:

Refractory
Synovial sarcoma
Tazemetostat
EZH2
Pathology
Medicine
Enhancer
Cancer research
relapsed refractory
Histone methyltransferase
multicenter study
Protein subunit

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations